Tuesday November 24 2009 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

BioPortfolio's Approved Drugs Database

Rapamune

Sirolimus

Download PDF containing detailed information.PDF Version

Image Results

Loading...

Press Releases About Rapamune:

 BioPortfolio Logo
NEVO(TM) Sirolimus-Eluting Coronary Stent Yields Superior Results to Taxus(R) Liberte(R) Stent in Pivotal Clinical Trial 19th May, 2009
BARCELONA, Spain, May 19 /PRNewswire/ -- At six months, the NEVO(TM) Sirolimus-eluting Coronary Stent, incorporating RES Technology(TM), was superior to the Taxus(R) Liberte(R) Stent in reducing
CYPHER SELECT(R) Plus Sirolimus-eluting Coronary Stent Now Approved in the European Union for Treatment of Patients With Diabetes 11th February, 2009
WARREN, New Jersey, February 11 /PRNewswire/ -- The CYPHER SELECT(R) Plus Sirolimus-eluting Coronary Stent has received CE marking within the European Union (EU) for treatment of patients with

This page has been viewed 28 times Browse BioPortfolio's InDepth service - alphabetically: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z or by Most Publications, recently searched for, or most viewed.

Search for Rapamune across BioPortfolio, or for Rapamune Research Reports
Wikipedia excerpt, where present, licenced under the GNU Free Documentation License. Resources from the NCBI applied. Selected MeSH subject headings created and maintained by the US NLM are used in conjunction with additional keywords. 2006-2008 MeSH. Thumbshots from Thumbshots.org

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.